The role of biomarkers of endothelial dysfunction in predicting the progression of mild cognitive impairment in patients with cardiovascular risk factors

Vorobeva O.V.; Fateeva V.V.

doi:https://doi.org/10.17116/jnevro202412409188

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

SPIN RSCI: 5084-1379
ORCID: 0000-0003-3259-3691

Fateeva V.V.

Pirogov Russian National Research Medical University;
Federal Scientific and Clinical Center for Resuscitation and Rehabilitology

ORCID: 0000-0001-9935-3962

The role of biomarkers of endothelial dysfunction in predicting the progression of mild cognitive impairment in patients with cardiovascular risk factors

Authors:

Vorobeva O.V., Fateeva V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9): 88‑95

DOI: 10.17116/jnevro202412409188

Read: 1555 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vorobeva OV, Fateeva VV. The role of biomarkers of endothelial dysfunction in predicting the progression of mild cognitive impairment in patients with cardiovascular risk factors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):88‑95. (In Russ.)
https://doi.org/10.17116/jnevro202412409188

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To develop a predictive model to assess the risk of progression of mild cognitive impairment (MCI) within 12 weeks in patients with cardiovascular risk factors using biomarkers of endothelial dysfunction.

MATERIAL AND METHODS

The study included 287 patients (mean age 64.3 years, 123 (42.9%) men) who met the inclusion criteria. All participants, at baseline and after 12 weeks, underwent neuropsychological testing using the Montreal Cognitive Assessment (MoCA) and laboratory blood tests to determine the levels of markers of endothelial inflammation (C-reactive protein (CRP), monocyte chemoattractant protein) and endothelial dysfunction (endothelin-1, endothelial NO-synthase (eNOS), endothelial growth factor, desquamated endothelial cells, S100B, von Willebrand factor, fibrinogen). During the study, patients took stable basic therapy. The demographic and anamnestic data, the results of neuropsychological testing and laboratory tests were used to construct a model of predictors that determine the trajectory of MCI using binary logistic regression, followed by calculation of its threshold indicator as a value for predicting the progression of MCI.

RESULTS

Age (p=0.00008), previous ischemic stroke (IS) (p=0.00001), MoCA index of executive functions ≤13 points (p=0.001) and MoCA index speech ≤6 points (p=0.024), eNOS ≥450 pg/ml (p=0.002), CRP ≥1 mg/ml (p=0.00006) and fibrinogen ≥4 g/l (p=0.0042) are independent predictors for the MCI progression. ROC-analysis showed a high predictive ability of the model with a threshold value of 0.4 (sensitivity 82.1%, specificity 72.3%).

CONCLUSION

Age, a history of IS, disorders of executive functions and speech, together with elevated values of CRP, fibrinogen, eNOS are important conditions for predicting the progression of MCI in patients with cardiovascular risk factors. These predictors and the risk of MCI progression calculated on their basis can be used as a tool for early diagnosis of dementia and in developing measures to prevent the progression of non-dementia cognitive impairment.

Keywords:

endothelial dysfunction

mild cognitive impairment

cardiovascular risk factors

prognosis

Authors:

Vorobeva O.V.

Chuvash state university named after I.N. Ulyanov

SPIN RSCI: 5084-1379
ORCID: 0000-0003-3259-3691

Fateeva V.V.

Pirogov Russian National Research Medical University;
Federal Scientific and Clinical Center for Resuscitation and Rehabilitology

ORCID: 0000-0001-9935-3962

Received:

03.06.2024

Accepted:

06.06.2024

Close metadata

References:

Levin OS. Predementia neurocognitive impairment in the elderly. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9-2):10-17. (In Russ.). https://doi.org/10.17116/jnevro201911909210
Bogolepova AN. Pathogenetic Approaches to Treatment of Chronic Cerebrovascular Insufficiency. Nervnye Bolezni. 2019;(3):16-20. (In Russ.). https://doi.org/10.24411/2226-0757-2019-12120
Mkhitaryan EA, Vorobieva NM, Tkacheva ON, et al. The prevalence of cognitive impairment and their association with socioeconomic, demographic and anthropometric factors and geriatric syndromes in people over 65 years of age: data from the Russian epidemiological study EVKALIPT. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):44-53. (In Russ.). https://doi.org/10.14412/2074-2711-2022-3-44-53
Yakhno NN, Tkacheva ON, Gavrilova SI, et al. Comprehensive interdisciplinary and interdepartmental program for prevention, early detection, diagnosis and treatment of cognitive disorders in older and senile people. Russian Journal of Geriatric Medicine. 2022;1:6-16. (In Russ.). https://doi.org/10.37586/2686-8636-1-2022-6-16
Vorobyeva OV, Sizova ZhM, Bogatyreva LM. Comparative study of pharmacological correction strategies for moderate cognitive impairment in hypertensive patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):52-59. (In Russ.). https://doi.org/10.14412/2074-2711-2019-2-52-59
Pantoni L, Gorelick PB. Cerebral small vessel disease. Cambridge University Press (UK). 2014.
Gorelick PB, Scuteri A, Black SE, et al. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
Dobrynina LA, Gadzhieva ZSh, Kremneva EI, et al. Survival, cognitive functions, and brain MRI in patients with cSVD: 5-year observation. Annals of Clinical and Experimental Neurology. 2022;16(4):18-28. (In Russ.). https://doi.org/10.54101/ACEN.2022.4.3
Vorob’eva OV. Cerebrovascular disease associated with metabolic syndrome: approaches to prevention and therapy. Neurology and Rheumatology (Suppl. Consilium Medicum). 2018;1:16-20. (In Russ.). https://doi.org/10.26442/2414-357X_2018.1.16-20
Soloveva EYu, Amelina IP. Cerebral small vessel disease’s impact on the development of chronic cerebral ischemia: paradigms of treatment. Meditsinskiy sovet = Medical Council. 2020;2:16-24. (In Russ.). https://doi.org/10.21518/2079-701X-2020-2-16-24
Veriugina NI, Chimagomedova ASh, Starovoitova IM, et al. Endothelial dysfunction in chronic vascular encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro20171176273-80
Fateeva VV, Vorob’eva OV. Nitric oxide: from the mechanism of action to pharmacological effects in cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):131-135. (In Russ.). https://doi.org/10.17116/jnevro2017117101131-135
Martynov MU, Bogolepova AN, Yasamanova AN. Endothelial dysfunction in COVID- 19 and cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):93-99. (In Russ.). https://doi.org/10.17116/jnevro202112106193
Vorob’eva OV, Fateeva VV, Nikulina KV, et al. Association between Peripheral Blood Inflammatory Markers, Endothelial Dysfunction Markers, and Depression. Association between peripheral blood inflammatory markers, endothelial dysfunction markers, and depression. London: IntechOpen; 2019. https://doi.org/10.5772/intechopen.88693
Voskresenskaya ON, Zakharova NB, Tarasova YS, et al. Possible mechanisms of cognitive dysfunction in patients with chronic forms of cerebrovascular diseases. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):32-36. (In Russ.). https://doi.org/10.14412/2074-2711-2018-1-32-36
Vorob’eva OV, Pilipovich AA, Fateeva VV. Impact of endothelial inflammation on depression in patients with cerebral microangiopathy: a prospective study. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):32-37. (In Russ.). https://doi.org/10.14412/2074-2711-2022-1-32-37
Biliutin-Aslanian RS, Vasilev AG. Influence of CRP on cognitive function of patients with combined and isolated forms of athero-sclerosis of cerebral and coronary vascular pools. Pediatrician (St. Petersburg). 2017;8(6):80-85. (In Russ.). https://doi.org/10.17816/PED8680-85
Dobrynina LA, Gnedovskaya EV, Zabitova MR, et al. Clustering of diagnostic MRI signs of cerebral microangiopathy and its relationship with markers of inflammation and angiogenesis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12-2):22-31. (In Russ.). https://doi.org/10.17116/jnevro202012012222
Quinn TJ, Gallacher J, Deary IJ, et al. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes. J Thromb Haemost. 2011;9:1475-1482. https://doi.org/10.1111/j.1538-7836.2011.04403.x
Poggesi A, Pasi M, Pescini F, et al. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. Journal of Cerebral Blood Flow & Metabolism. 2016;36:72-94. https://doi.org/10.1038/jcbfm.2015.116
Markus HS. Genes, endothelial function and cerebral small vessel disease in man. Exp Physiol. 2007;93(1):121-127. https://doi.org/10.1113/expphysiol.2007.038752
Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19(3):271-278. https://doi.org/10.1016/S1474-4422(19)30368-0
Busse A, Angermeyer MC, Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189:399-404. https://doi.org/10.1192/bjp.bp.105.014779
Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol. 2023;22(7):602-618. https://doi.org/10.1016/S1474-4422(23)00131-X
Julayanont P, Brousseau M, Chertkow H, et al. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer’s disease. J Am Geriatr Soc. 2014;62(4):679-684. https://doi.org/10.1111/jgs.12742
Wang L, Yang L, Liu H, et al. C-Reactive Protein Levels and Cognitive Decline following Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Brain Sci. 2023;13(7):1082. https://doi.org/10.3390/brainsci13071082
Ji W, Wang C, Chen H, et al. Predicting post-stroke cognitive impairment using machine learning: A prospective cohort study. J Stroke Cerebrovasc Dis. 2023;32(11):107354. https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107354
Pyun JM, Ryoo N, Park YH, et al. Fibrinogen Levels and Cognitive Profile Differences in Patients with Mild Cognitive Impairment. Dement Geriatr Cogn Disord. 2020;49(5):489-496. https://doi.org/10.1159/000510420
Xu G, Zhang H, Zhang S, et al. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int J Clin Pract. 2008;62(7):1070-1075. https://doi.org/10.1111/j.1742-1241.2007.01268.x